#AKTInhibitor
LightNews LightNews
oncodaily.bsky.social
First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer

https://oncodaily.com/insight/prostate-cancer-192144

astrazeneca.bsky.social

##AKTInhibitor ##AKTInhibitorCombination ##AstraZeneca ##Cancer ##OncoDaily ##Oncology ##ProstateCancer ##Medicine
First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer - OncoDaily
First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer / AKT inhibitor, AKT inhibitor combination, André
oncodaily.com
December 2, 2024 at 9:01 PM
hemehub.bsky.social
🩺💡Today’s clinical questions!

Swipe to see the answers and explanations!

#Engasertib #AKTInhibitor #AKTPathway #BreastCancer #Oncology #CancerResearch #ClinicalTrials #Phase1Trial #NEJM #MedicalEducation #OncologyEducation #MedEd #CancerCare #AdverseEvents #OncTwitter #HemeOnc #HEMEHUB
June 25, 2026 at 2:00 AM